NCT04158635View on ClinicalTrials.gov

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

January 27, 2026

Study Completion Date

January 27, 2026

Conditions
Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Carcinoma
Interventions
DRUG

Bosentan

Given PO

DRUG

Gemcitabine

Given IV

DRUG

Nab-paclitaxel

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER